NeOnc Phase 2a brain cancer trial shows 48.9% survival vs. 20% benchmark Aug 12, 2026 09:27AM
NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x Aug 12, 2026 09:25AM
NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence Aug 11, 2026 08:44AM
WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy Jun 22, 2026 08:45AM
WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates Jun 15, 2026 08:35AM


Jun 9, 2026 08:45AM The Race to Defeat Brain Cancer Could Become One of the Biggest Biotech Stories of the Decade